Bisphosphonates remain the first-line medication for most people with osteoporosis, according to 2026 guidelines from the American College of Physicians (ACP). However, the treatment landscape has shifted significantly, with new medications entering the picture and updated recommendations about when to start with bone-building drugs instead. Understanding where bisphosphonates fit in your treatment plan requires looking at your individual fracture risk, not just your bone density score. Why Did Bisphosphonates Become the Clear First Choice Again? Bisphosphonates have been used to treat osteoporosis since the 1990s and work by slowing bone loss. They reduce the activity of osteoclasts, which are cells that break down bone. The 2023 ACP guidelines represented a notable shift from their 2017 position, which treated bisphosphonates and denosumab (Prolia) as roughly equivalent starting options. The updated 2023 guidance clearly states that for postmenopausal women and men with primary osteoporosis, treatment should start with a bisphosphonate. This recommendation reflects the latest evidence and clinical experience showing that bisphosphonates effectively reduce fracture risk across a broad range of patients. However, there is one major exception to this rule that deserves careful attention. When Should You Start With Bone-Building Drugs Instead? For individuals at very high risk of fracture, current guidelines recommend a different approach. This includes people with severe osteoporosis, multiple prior fractures, or very low bone density. For these patients, experts recommend starting with an anabolic agent like EVENITY (romosozumab) or Forteo (teriparatide) for one to two years, followed by a bisphosphonate to preserve the bone gains. Research shows that this sequence produces significantly better results than starting with a bisphosphonate. A landmark study found that starting with an anabolic agent followed by a bisphosphonate produces greater total bone density gains than the reverse sequence. This is an important conversation to have with your doctor if you are at very high risk of fracture and being offered a bisphosphonate as your first treatment. How to Determine If You Need Bisphosphonate Treatment - Fracture Risk Assessment: The decision depends on your overall fracture risk, not just your bone density score. The World Health Organization's FRAX tool estimates your 10-year probability of fracture by combining your bone density with other risk factors including age, weight, fracture history, family history, smoking, alcohol use, and steroid use. - Treatment Thresholds: In the United States, treatment guidelines generally recommend considering bisphosphonates when your 10-year hip fracture risk exceeds 3% or your major osteoporotic fracture risk exceeds 20%. In Canada, pharmaceutical intervention is typically considered when your major fracture risk exceeds 20%, with those in the moderate range of 10-20% evaluated on a case-by-case basis depending on additional risk factors. - Osteopenia Considerations: A T-score between -1 and -2.5 (the osteopenia range) does not automatically mean you need a bisphosphonate. However, the 2023 ACP guidelines suggest that for women over 65 with low bone mass, clinicians should take an individualized approach, and if treatment is initiated, a bisphosphonate should be used. A landmark 2018 study called the HORIZON trial extension showed that zoledronic acid (Reclast) significantly reduced fractures even in women with osteopenia, not just those with full osteoporosis. This was a major finding because most earlier bisphosphonate trials had focused exclusively on people with T-scores below -2.5. The patients who benefit most from bisphosphonate treatment in the osteopenia range are those with additional risk factors. These include a previous fracture, a strong family history of hip fracture, long-term steroid use, or a history of falls. If your only finding is mild osteopenia with no other risk factors, your doctor may instead recommend monitoring, adequate calcium and vitamin D, and a targeted exercise program. What Happens After You Finish Anabolic Treatment? If you have just completed a 12-month course of EVENITY or up to two years of Forteo, transitioning to a bisphosphonate is not optional; it is essential. Anabolic medications build new bone during the treatment period, but once you stop taking them, those gains begin to reverse without follow-on therapy. Research from the FRAME trial shows that without follow-on antiresorptive therapy, patients can lose the majority of their bone density gains within 12 months of completing anabolic treatment. A bisphosphonate slows down the osteoclasts, the bone-removing cells, preserving the new bone created during your anabolic treatment phase. Both oral alendronate and intravenous zoledronic acid (Reclast) have been used as follow-on therapy after EVENITY. The ARCH trial used alendronate and demonstrated significantly lower fracture risk with the romosozumab-to-alendronate sequence than alendronate alone. Zoledronic acid is also commonly chosen because its once-yearly dosing may improve long-term adherence. Current practice typically involves starting the bisphosphonate approximately one to two months after your final EVENITY injection. Your doctor should arrange a DEXA scan around the time of your transition to measure the bone density gains from EVENITY and establish a new baseline. Bone turnover markers may also be monitored at 6 and 12 months after the switch. Key Takeaways for Your Bone Health The updated 2026 guidelines make clear that bisphosphonates remain the foundation of osteoporosis treatment for most patients. However, the treatment landscape is more nuanced than ever. Your doctor should evaluate your complete fracture risk profile using tools like the FRAX assessment, not just your bone density score. If you are at very high risk, starting with an anabolic agent followed by a bisphosphonate may produce better long-term results. And if you have completed anabolic treatment, transitioning to a bisphosphonate is critical to preserve your bone gains. Having an informed conversation with your physician about where bisphosphonates fit in your specific situation is the best first step toward protecting your bone health.
